Exhibit 10.13

 


EXECUTIVE EMPLOYMENT AGREEMENT


 


This Executive Employment
Agreement (“Agreement”) is made and entered into by Humacyte, Inc. (“Humacyte” or the “Company”)
and Laura Niklason, M.D., Ph.D. (hereinafter “Executive”) effective November 9, 2020.


 


WHEREAS, the Company has
employed Executive as its President and Chief Executive Officer effective November 9, 2020, and the parties desire to confirm such
employment on the terms set forth below.


 


NOW THEREFORE, in consideration
of the mutual promises set forth below and other good and valuable consideration, the receipt and sufficiency of which the parties
acknowledge, the Company and Executive agree as follows:


 


1. NATURE OF
EMPLOYMENT AND DUTIES. Executive shall serve as Company’s President and Chief Executive Officer, effective on the
date first written above (the “Effective Date”) and have such responsibilities and authority as the Company may lawfully
assign from time to time. Additionally, Executive agrees to perform such other duties consistent with those of an executive at
her level as the Company may lawfully direct from time to time. Executive shall report to the Company’s Board of Directors
and, upon appointment by the Company’s shareholders, shall serve as a member of the Company’s Board of Directors.


 


1.1 Executive shall perform
all duties and exercise all authority in accordance with, and otherwise comply with, all lawful Company policies, procedures, practices
and directions.


 


1.2 Executive shall devote
all of her working time, reasonable best efforts, knowledge and experience to perform her duties and advance the Company’s
interests. During her employment, Executive shall not, directly or through others, engage in, assist or consult with any other
business or business activities of any nature whatsoever (including board memberships) without the Company’s prior written
consent; provided, however, this provision does not prohibit her from personally owning and trading in stocks, bonds, securities,
real estate, commodities or other investment properties for her own benefit which do not create actual or potential conflicts of
interest with the Company; nor does it prohibit her from serving on advisory boards, so long as such service does not violate her
obligations under the Non-Competition Agreement, as defined herein, or distract her from her duties under this Agreement. Notwithstanding
the foregoing, Executive shall continue to be permitted to continue her current relationship with Yale University as an adjunct
professor.


 


2. COMPENSATION.


 


2.1 Base Salary.
Executive’s annual base salary for all services rendered shall be Five Hundred Thousand and No/100 Dollars ($500,000.00)
(less applicable taxes and withholdings), payable in accordance with the Company’s policies, procedures and practices as
they may exist from time to time. Executive’s base salary shall be reviewed by the Company’s Board of Directors in
accordance with the Company’s policies, procedures, and practices as they may exist from time to time. Executive’s
base salary shall not be reduced except in connection with an across the board reduction of all similarly situated executives in
an amount not to exceed ten percent (10%) of the Executive’s then current base salary.


 






    	 



    	



    

 


2.2 Benefits.
Executive may participate in all medical, dental and disability insurance, Simple IRA, 401(k), profit sharing, pension, personal
leave, and other employee benefit plans and programs that may be made available from time to time to senior employees of the Company
provided, however, that Executive’s participation in any such benefit plans and programs is subject to the applicable terms,
conditions and eligibility requirements of these plans and programs, some of which are within the plan administrator’s discretion,
as they may exist from time to time. Notwithstanding anything to the contrary in the foregoing, Executive shall be entitled to
four (4) weeks of vacation each year.


 


2.3 Business Expenses.
Executive shall be reimbursed for reasonable expenses actually incurred by her in performing services under this Agreement in accordance
with and subject to the terms and conditions of the applicable Company reimbursement policies, procedures and practices as they
may exist from time to time.





 


2.4 Annual Incentive
Bonus. Executive shall be eligible for consideration for an annual incentive bonus of up to fifty percent (50%) of Executive’s
then current base salary in accordance with objectives to be determined between the Company and Executive. Any bonus shall be awarded
in the Board’s sole discretion taking into consideration Executive’s achievement of the agreed upon objectives. Except
as expressly provided otherwise herein, by Company policy, or by the terms of any annual bonus plan, Executive must be employed
on the date any such annual incentive bonus is paid in order to receive such bonus and the bonus is not earned unless the Executive
is employed on that date; however, if Executive’s employment is terminated by the Company without Cause or by the Executive
for Good Reason before the payment date, then Executive shall earn any bonus awarded for the prior fiscal year that had not been
paid prior to such termination and a pro rata portion of the bonus that the Board awards for the current fiscal year, with the
pro rata portion calculated based on the number of days that Executive was employed during the relevant fiscal year prior to termination.


 


2.5 Stock Option Grant.
Executive will be eligible to continue to participate in the Company’s Omnibus Incentive Plan (as amended from time to time,
the “Plan”) in accordance with the terms and conditions of the Plan. The Company shall award her an additional stock
option grant of 5,000,000 shares (the “Option Shares”) (in addition to the options awarded to Executive prior to this
Agreement). Subject to Executive’s Stock Option Agreement, one-third of the 5,000,000 shares will vest on each of the three
anniversaries after November 9, 2020. All grants under the Plan, and the terms of all such grants, are subject to and must be approved
by the Board, and the stock option grant referenced above remains subject to the Board’s review and approval. If approved,
Executive will be required to execute the Company’s standard Stock Option Agreement as a prerequisite to participation in
the Plan. The Option Shares shall fully vest upon a Corporate Transaction (as defined in the Plan).


 


2.6 Living Expenses.
The Company shall reimburse Executive for the cost of an apartment and living expenses in the Durham, North Carolina area in an
amount not to exceed sixty thousand dollars ($60,000) per year.


 






    	2



    	



    

 


2.7 Modifications.
Nothing in this Agreement shall require the Company to create, continue or refrain from amending, modifying, revising or revoking
any of the plans, programs or benefits described in Sections 2.2, 2.3, 2.4 and 2.5. Any amendments, modifications, revisions and
revocations of these plans, programs and benefits shall apply to Executive.


 


3. TERMINATION
OF EMPLOYMENT. Executive’s employment shall continue from the Effective Date until terminated as provided herein.


 


3.1 Termination Without
Cause. Either party may terminate this Agreement and the employment relationship hereunder without cause at any time upon giving
the other party thirty (30) days’ prior written notice.


 


3.2 Termination by
the Company for Cause. The Company may terminate this Agreement and Executive’s employment hereunder immediately without
notice at any time for the following reasons which shall constitute “Cause” for purposes of this Agreement:


 


(a) Executive’s
death;


 


(b) Executive’s
physical or mental disability that prevents her from performing the essential functions of her duties satisfactorily for a period
of one hundred eighty (180) consecutive days or one hundred eighty (180) days in total within any 365 consecutive-day period as
determined by the Company in its reasonable discretion and in accordance with applicable law;


 


(c) any act or omission
of Executive constituting knowing and willful misconduct (including knowing and willful violation of material Company’s policies);


 


(d) gross negligence;


 


(e) fraud, misappropriation,
embezzlement;


 


(f) conviction of a non-traffic
related felony;


 


(g) violation of the
Company’s conflict of interest policy or engaging in competitive business activities in violation of this Agreement; or


 


(h) Executive’s
material breach of this Agreement or breach of the Non-Competition Agreement.


 


Provided however, prior to a termination for
Cause based on Sections 3.2 (c), (d), (g), or (h), the Company shall provide Executive with written notice of the alleged basis
for termination and a thirty (30) day opportunity to cure. For the avoidance of doubt, “Cause” shall not exist under
Sections 3.2 (c), (d), (g), or (h) if Executive cures the alleged basis for termination within the thirty (30) day cure period.


 


3.3 Termination by
Executive for Good Reason. Executive may terminate this Agreement and Executive’s employment hereunder for the following
reasons which shall constitute “Good Reason” for purposes of this Agreement: (a) the Company’s material breach
of this Agreement; or (b) a material adverse change, by the Company without Executive’s consent, in or to Executive’s
salary, expense reimbursement rights, bonus eligibility, authority or responsibilities, provided that Executive may only terminate
for Good Reason if she provides the Company with written notice of the existence of the condition giving rise to Good Reason within
thirty (30) days of its initial existence, the Company has not cured the condition within thirty (30) days of the notice, and if
the Company fails to cure the condition within such cure period, Executive terminates employment within seven (7) days after the
end of the cure period.


 






    	3



    	



    

 


3.4 Survival.
This Agreement shall terminate upon the termination of the employment relationship established hereunder with the following exceptions:
Section 4 (Compensation and Benefits Upon Termination), Section 5 (Non-Competition) and Section 13 (Section 409A) shall survive
the termination of Executive’s employment and/or the expiration or termination of this Agreement, regardless of the reasons
for such expiration or termination.


 


4. COMPENSATION
AND BENEFITS UPON TERMINATION.


 


4.1 The Company’s
obligation to compensate Executive ceases on the effective termination date except as to: (a) amounts due or earned at that time;
and (b) any compensation and/or benefits which she may be entitled to receive pursuant to Section 4.2.


 


4.2 If the Company terminates
Executive’s employment pursuant to Section 3.1 (without Cause) or if Executive terminates Executive’s employment pursuant
to Section 3.3 (Good Reason), then the Company’s sole obligations shall be to pay Executive:


 


(a) amounts due on the
effective termination date; and


 


(b) an amount equal to
twelve (12) months of Executive’s then current base salary (less any applicable taxes and withholdings) with payment of such
amount to be made in substantially equal installments on the same payroll schedule applicable to Executive immediately prior to
her separation from service. Such payments shall commence on the first such payroll date following the sixtieth (60th)
day following her separation from service provided that she has returned by such sixtieth (60th) day an executed, customary
Release of all claims provided by the Company and any revocation period in the Release has expired without a revocation occurring.
In addition, the Company shall pay Executive any accrued, earned and unpaid bonus pursuant to Section 2.4. The Company will also
reimburse the Executive for the cost to continue Executive’s and her family’s health insurance under COBRA for a period
of twelve (12) months.


 


4.3 If the Company terminates
Executive’s employment for Cause as provided in Section 3.2 or if Executive terminates her employment pursuant to Section
3.1 (without Good Reason), then the Company’s sole obligation shall be to pay Executive amounts due or earned on the effective
termination date. Executive, except when employment terminates pursuant to Section 3.2(a) (death), shall continue to be subject
to Section 5 of this Agreement upon expiration or termination of this Agreement.


 


4.4 The Company’s
obligation to provide the payment and benefits under Section 4.2 is conditioned upon Executive’s execution of an enforceable
release of all claims (“Release”) and her compliance with the Non-Competition Agreement, as defined herein. If Executive
chooses not to execute the Release (or revokes the Release) or fails to comply with the Non-Competition Agreement, then the Company’s
obligation to compensate her shall cease on the effective termination date except as to amounts due as of the date of termination.
The Release shall be provided to Executive within seven (7) days of her separation from service, and Executive must execute it
within the time period specified in the Release, which shall not be longer than forty-five (45) days from the date of receipt.
Such Release shall not be effective until any applicable revocation period has expired.


 






    	4



    	



    

 


4.5 Executive is not
entitled to receive any compensation or benefits upon her termination except as set forth in this Agreement or otherwise required
by any employee benefit plan in which she participates. Moreover, the terms and conditions afforded Executive under this Agreement
are in lieu of any severance benefits to which she otherwise might be entitled pursuant to any severance plan, policy and practice
of the Company. Nothing in this Agreement, however, is intended to waive or supplant any death, disability, or other insurance
or retirement, 401(k) or pension benefits to which she may be entitled under employee benefit plans in which she participates.


 


5. NON-COMPETITION.
As part of the consideration for the compensation and benefits to be paid to Executive hereunder, including without limitation
the grant of stock options and as additional incentive for the Company to enter into this Agreement, Executive agrees to execute
and to abide by the Proprietary Information, Inventions, and Non-Competition Agreement (the “Non-Competition Agreement”)
attached hereto as Exhibit A.


 


6. EMPLOYEE REPRESENTATION.
Executive represents and warrants that to her knowledge her employment and obligations under this Agreement will not (a) breach
any duty or obligation she owes to another or (b) violate any law, recognized ethics standard or recognized business custom.


 


7. NOTICES.
All notices, requests, demands and other communications required or permitted to be given in writing pursuant to this Agreement
shall be deemed given and received: (a) upon delivery if delivered personally; (b) on the next day after being deposited with a
reliable overnight delivery service; or, (c) upon receipt of an answer back confirmation, if transmitted by email, addressed to
the below indicated e-mail address. Notice given in another manner shall be effective only if and when received by the addressee.
For purposes of notice, the addresses of the parties shall be as follows:


 


	If to the Executive, to :	Laura E. Niklason MD, PhD
	 	CEO, Humacyte
	 	2525 E. NC Highway 54
	 	Durham, NC 27713
	 	[***]
	 	 
	If to the Company, to:	Chief Financial Officer
	 	Humacyte, Inc.
	 	P.O. Box 12695
	 	Durham, North Carolina 27709
	 	[***]


 





    	5



    	



    

 


provided that: (a) each party shall have the
right to change its address for notice, and the person who is to receive notice, by the giving of fifteen (15) days’ prior
written notice to the other party in the manner set forth above; and (b) notices shall be effective if given to the other party
in the manner set forth above regardless of whether a copy was received by any additional addressee specified above.


 




8. WAIVER OF
BREACH. The Company’s or Executive’s waiver of any breach of a provision of this Agreement shall not waive
any subsequent breach by the other party.


 


9. SEVERABILITY.
If a court of competent jurisdiction holds that any provision or sub-part thereof contained in this Agreement is invalid, illegal
or unenforceable, that invalidity, illegality or unenforceability shall not affect any other provision in this Agreement.


 


10. PARTIES BOUND;
ASSIGNMENT. The terms, provisions, covenants and agreements contained in this Agreement shall apply to, be binding upon
and inure to the benefit of the Company’s successors and assigns. The Company, at its discretion, may assign this Agreement
to its successors or affiliates. Because this Agreement is personal to Executive, Executive may not assign this Agreement.


 


11. GOVERNING
LAW. This Agreement and the employment relationship created by it shall be governed by North Carolina law without giving
effect to North Carolina choice of law provisions. The parties hereby consent to jurisdiction in North Carolina for the purpose
of any litigation relating to this Agreement and agree that any litigation by or involving them relating to this Agreement shall
be conducted in the courts of Wake County, North Carolina, or the federal courts of the United States for the Eastern District
of North Carolina.


 


12. SECTION 409A
OF THE INTERNAL REVENUE CODE.


 


12.1 Parties’
Intent. The parties intend that the provisions of this Agreement comply with Section 409A of the Internal Revenue Code of 1986,
as amended (the “Code”), and the regulations thereunder (collectively, “Section 409A”) and all provisions
of this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Section
409A. If any provision of this Agreement (or of any award of compensation, including equity compensation or benefits) would cause
Executive to incur any additional tax or interest under Section 409A, the Company shall, upon the specific request of Executive,
use its reasonable business efforts to in good faith reform such provision to comply with Section 409A; provided, that, to the
maximum extent practicable, the original intent and economic benefit to Executive and the Company of the applicable provision shall
be maintained, and the Company shall have no obligation to make any changes that could create any additional economic cost or loss
of benefit to the Company. The Company shall timely use its reasonable business efforts to amend any plan or program in which Executive
participates to bring it in compliance with Section 409A. Notwithstanding the foregoing, the Company shall have no liability with
regard to any failure to comply with Section 409A so long as it has acted in good faith with regard to compliance therewith.


 






    	6



    	



    

 


12.2 Separation from
Service. A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing
for the payment of any amounts or benefits upon or following a termination of employment unless such termination also constitutes
a “Separation from Service” within the meaning of Section 409A and, for purposes of any such provision of this Agreement,
references to a “termination,” “termination of employment,” “separation from service” or like
terms shall mean Separation from Service.


 


12.3 Separate Payments.
Each installment payment required under this Agreement shall be considered a separate payment for purposes of Section 409A.


 


12.4 Delayed Distribution
to Specified Employees. If the Company determines in accordance with Section 409A and 416(i) of the Code and the regulations
promulgated thereunder, in the Company’s sole discretion, that the Executive is a specified employee of the Company, determined
in accordance with Section 409A, any payments and/or benefits provided under this Agreement that constitute “nonqualified
deferred compensation” subject to 409A that are provided to Executive on account of her Separation from Service shall not
be provided until the day after the six-month anniversary of Executive’s termination date (“Specified Employee Payment
Date”). The aggregate amount of any payments that would otherwise have been made to Executive during such six-month period
shall be paid in a lump sum to Executive on the Specified Employee Payment Date without interest and, thereafter, any remaining
payments and/or benefits shall be paid without delay in accordance with their original schedule.


 


13. ENTIRE AGREEMENT.
Except as expressly provided herein and except for the Non-Competition Agreement and existing and new Stock Option Agreements,
this Agreement: (a) supersedes all other understandings and agreements, oral or written, between the parties with respect
to the subject matter of this Agreement, Executive’s employment or prior consulting arrangements with the Company, including
but not limited to the Memorandum of Understanding, effective September 14, 2016, between the Company and Executive; and (b) constitutes
the sole agreement between the parties with respect to the subject matter hereof. Each party acknowledges that: (i) no representations,
inducements, promises or agreements, oral or written, have been made by any party or by anyone acting on behalf of any party, which
are not embodied in this Agreement; and (ii) no agreement, statement or promise not contained in this Agreement shall be valid.
No change or modification of this Agreement shall be valid or binding upon the parties unless such change or modification is in
writing and is signed by the parties.


 






    	7



    	



    

 


IN WITNESS WHEREOF, the
parties have entered into this Agreement effective on the day and year first written above.


 


	 	EXECUTIVE
	 	 
	 	/s/ Laura E. Nicklason
	 	Laura E. Niklason MD, PhD
	 	 
	 	HUMACYTE, INC.
	 	 
	 	/s/ Douglas Blankenship
	 	By:    Douglas Blankenship
	 	Title: Chief Financial Officer




 



    	8